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1446.e1 The Journal of Thoracic and CaObjective: Primary graft failure remains a significant cause of morbidity and
mortality after lung transplantation, and its mechanism is not understood. Previously
2 case reports described fatal primary graft failure due to donor-related unexpected
pulmonary embolism. This study investigated the incidence, early outcome, and risk
factors of unexpected pulmonary embolism in lung transplantation.
Methods: An exploratory retrograde donor lung flush before implantation to diag-
nose pulmonary embolism (emboli group) or no pulmonary embolism (no-emboli
group) was performed in 74 of 122 consecutive lung transplantations.
Results: The incidence of macroscopic unexpected pulmonary embolism was 38%
(28% clot and 9% fat). In the emboli group, significantly decreased oxygenation
(P  .05), increased pulmonary vascular resistance (P  .001), an increased
proportion of opacity on chest radiograph (P  .03), prolonged intubation (P 
.001) and intensive care unit stay (P .01), and decreased 1-year survival (P .03)
were seen after transplantation. In multivariate analysis, pulmonary embolism was
an independent risk factor for prolonged intubation (hazard ratio, 2.42; P  .01). In
logistic regression, death due to trauma with fracture and a smoking history of more
than 20 pack-years were significant donor risk factors for pulmonary embolism
(adjusted odds ratio, 8.77 and 5.64; P  .02 and .04, respectively). No deleterious
effects of the exploratory flush were seen.
Conclusions: Unexpected pulmonary embolism is relatively common, is potentially
predicted by donor history (but not by arterial blood gas analysis or chest radio-
graph), and is associated with primary graft failure. Donor lungs with risk factors of
pulmonary embolism should undergo an exploratory flush. When pulmonary em-
bolism is diagnosed, further therapeutic strategies must be considered.
Standardized donor lung selection criteria have been widely used to ensurequality donor organs for lung transplantation. Recently, extended donorselection criteria have also been used, with acceptable outcomes.1-4 However,
primary graft failure (PGF)—characterized by pulmonary infiltrates, impaired ox-
ygenation, diminished lung compliance, and diffuse alveolar damage on histologic
analysis—remains a significant cause of morbidity and mortality after lung trans-
plantation. The mechanism of PGF has not been elucidated.5-7
Previously 2 case reports described fatal PGF that was caused by donor-related
pulmonary emboli diagnosed by lung biopsy after transplantation.8,9 These case
reports suggested that, occasionally, donor selection criteria, which are traditionally
based on age, chest radiograph and bronchoscopy findings, respiratory and smoking
history, quality and volume of sputum, and blood gas results, might fail to identify
donor lungs with a major pathologic process, such as donor-related unexpected
pulmonary embolism (PE). Furthermore, the incidence of unexpected PE in donor
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plantation remain unknown because of the difficulty of
detecting PE, especially before transplantation.
To further explore the relationship of unexpected PE
with PGF, we used a simple exploratory method of a brief
retrograde donor lung flush before implantation. The aims
of this study were to describe the incidence of unexpected
PE in donor lungs that were accepted for transplantation, to
investigate the early outcomes after lung transplantation,
and to investigate the risk factors for unexpected PE.
Materials and Methods
From April 2002 to April 2005, a total of 122 consecutive lung
transplantations, including 86 bilateral single-lung and 36 single-
lung transplantations, were performed at the Alfred Hospital, and
all of these were included in this study.
Donor and Recipient Assessment and Matching
Although lung donor selection criteria are based on standard
criteria, extended donors are commonly used at our institu-
tion.2,6,10,11 Preoperative immunologic evaluation was routinely
performed. The presence of preformed antibodies to human leu-
kocyte antigen was screened with a panel-reactive antibody assay,
and all transplant recipients were found to have values less than
10%. A prospective donor-recipient T-cell and B-cell cross-match
was performed in all cases.
Lung Procurement
Lung procurement and preservation basically followed standard
procedures.12-14 This included an intravenous infusion of prosta-
cyclin (Flolan) at 40 to 80 ng · kg1 · min1 for approximately 10
minutes before crossclamping, followed by a single antegrade
flush with cold modified Euro-Collins solution (60 mL/kg). After
September 2004, Perfadex (Vitrolife, Göteborg, Sweden) replaced
Euro-Collins solution at our institution.
Exploration of Unexpected PE
We used a simple exploratory method to detect unexpected PE in
donor lungs.15 Before implantation, a brief retrograde flush was
performed via pulmonary venous cuff on a back table. Approxi-
mately 50 to 70 mL of cold Ringer solution was gently flushed by
a selectively cannulated ball syringe for each pulmonary venous
segmental branch. Details of macroscopic PEs flushed out of the
pulmonary arteries were recorded. When any PE was detected, a
brief flush was repeated until no further PE was flushed out. An
Abbreviations and Acronyms
CPB cardiopulmonary bypass
FIO2  inspired oxygen fraction
ICU  intensive care unit
PE  pulmonary embolism
PGF  primary graft failure
PVR pulmonary vascular resistanceexploratory flush became routine practice in our institution in
The Journal of Thoracic anFebruary 2004. Before then, exploratory flushing was performed
when indicated by the appearance of possible small pulmonary
infarcts or contusions in the donor lung, protracted donor inpatient
stay, the surgeon’s preference, and donors who died of, especially,
multiple traumas.
Transplantation Procedure
Cardiopulmonary bypass (CPB) was not routinely performed in
our institution except for pulmonary hypertension. CPB was con-
sidered in cases of intolerance of single-lung ventilation due to
hemodynamic instability.12 Before completion of implantation,
retrograde reperfusion and deairing was performed via an untied
pulmonary arterial anastomotic suture line. A specific pressure-
and flow-controlled technique was not used. This was then fol-
lowed by antegrade reperfusion.
Postoperative Management
Postoperative management in the intensive care unit (ICU) was
performed to ensure satisfactory end-organ perfusion while a rel-
atively low filling pressure was maintained (cardiac index 2.4,
pulmonary capillary wedge pressure 10 mm Hg, and central
venous pressure 7 mm Hg). Patients with PGF received a stan-
dardized evaluation and therapy with increasing complexity
depending on the degree of ventilatory and hemodynamic
compromise.6,16
Immunosuppression and Surveillance of
Transbronchial Lung Biopsy
Immunosuppression was based on triple therapy with cyclosporine
(trough levels of 300-450 g/L), azathioprine (1.5-2.0 mg ·
kg1 · d1), and prednisolone (0.15 mg · kg1 · d1). Prophylaxis
for Pneumocystis carinii and cytomegalovirus infection was
achieved with low-dose oral trimethoprim-sulfamethoxazole
and intravenous and oral ganciclovir, respectively. Surveillance
bronchoscopy and transbronchial lung biopsy were performed
at 0.5, 1, 2, 3, 6, 9, 12, 18, and 24 months and yearly thereafter.
Acute rejection was defined and treated according to standard
criteria.3,16,17
Data Collection
Data regarding PE were recorded prospectively; however, other
data were retrieved retrospectively from the transplant database
and from a review of ICU and donor records. Arterial blood gas
analysis data and pulmonary vascular resistance (PVR) data were
collected at 0, 6, 12, 18, and 24 hours after admission to the ICU.
The donor PaO2 was the last arterial blood gas result on an inspired
oxygen fraction (FIO2) of 1.0 and a positive end-expiratory pres-
sure of 5 cm H2O recorded at the time of donor referral to the
transplantation center. The graft ischemic time of a bilateral single-
lung transplantation was defined as the ischemic time for the
second transplanted lung. The degree of opacification on the chest
radiograph at the time of donor referral and 24 hours after trans-
plantation was assessed and scored by 2 blinded reviewers as
follows: clear, no infiltrate; mild, mild interstitial infiltrate in less
than 1 lobe; and moderate/severe, moderate to severe interstitial
infiltrate in more than 1 lobe or extensive alveolar infiltrate.
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The PaO2/FIO2 ratio, PVR, chest radiograph, duration of intubation,
length of ICU stay, time free from acute rejection, lung function 3
months after transplantation, and 1-year survival were used as
outcome indicators.
Study Groups
First, we divided the recipients who received lungs with an ex-
ploratory flush (exploratory flush group) and recipients who re-
ceived lungs without an exploratory flush (no-flush group). Sec-
ond, to investigate the incidence and effect of PE, we divided the
exploratory flush group into the following 2 groups according to
the result of the exploratory flush: recipients who received lungs
with PE that included clot and fat (emboli group) and recipients
who received lungs without any PE (no-emboli group). Third, the
emboli group was subgrouped by the material of the PE.
Statistical Analysis
Analysis was performed with the StatView 5.0 software package
(SAS Institute, Inc, Cary, NC). Continuous data were initially
assessed for normality and expressed as mean  SE; categorical
data were expressed as count and proportions. Comparison be-
tween groups was performed with the 2 test for categorical
variables, with the Student t test for parametric continuous vari-
ables, and with the Mann-Whitney U test for nonparametric con-
tinuous variables, if appropriate. Repeated-measures variables,
including the PaO2/FIO2 ratio and PVR, were analyzed with 2-way
repeated-measures analysis of variance. Duration of intubation,
length of ICU stay, time to first acute rejection, and 1-year survival
were estimated by the Kaplan-Meier method, and the curves were
analyzed by using the log-rank test. Univariate and multivariate
analysis for duration of intubation, length of ICU stay, and 1-year
survival were performed by using Cox proportional hazards re-
gression, and risk factors for PE were analyzed with logistic
regression. All possible prediction variables were put into the
Figure 1. A, Arterial oxygen tension/inspired oxygen
plantation. B, Pulmonary vascular resistance in the fi
between the emboli and no-emboli groups. *P < .05;univariate analysis, including donor age, sex, cause of death,
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apy use, preprocurement intubation time, prophylactic anticoagu-
lant therapy, last PaO2, and PE in donor lungs, as well as recipient
age, sex, underlying disease, type and year of transplantation, graft
ischemic time, and use of CPB. Risk factors with a level of
significance defined as P  .20 in univariate analysis were ad-
justed in the multivariate analysis.
Results
Incidence and Character of Unexpected PE
An exploratory flush was performed for 74 of 122 lung
transplants (Table E1; see online-only materials). PE was
detected in 28 of 74 donors, and the incidence of PE was
38%. Twenty-one of 28 PEs were clot emboli, and 7 were
fat emboli. The demographics of donors and recipients were
similar between the emboli and no-emboli groups except for
CPB use (P  .05). In the emboli group, 7 patients required
CPB because of preexisting pulmonary hypertension, and 2
required it because of intolerance of single-lung ventilation
during the second lung implantation.
Oxygenation Before and After Transplantation
The PaO2/FIO2 ratio before procurement and after transplan-
tation is depicted in Figure 1, A. Although the PaO2/FIO2
ratio before procurement was similar between groups, the
PaO2/FIO2 ratio in the emboli group was significantly worse
than that in the no-emboli group throughout the first 24
hours after admission to the ICU.
Pulmonary Vascular Resistance
PVR in the no-emboli group decreased constantly in the first
24 hours after admission to the ICU; however, the PVR in
the emboli group remained significantly higher than that in
umption ratio (PaO2/FIO2 ratio) before and after trans-
4 hours after transplantation. Comparison was made
.01; ‡P < .001.cons
rst 2
†P <the no-emboli group (Figure 1, B).
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The relative proportion of opacity scores of donor chest
radiographs was similar between groups (P  .52); approx-
imately 60% of donors had a clear chest radiograph (Figure
E1, A) . After transplantation, an increased proportion in mild
to severe opacity on chest radiograph categories was seen in
the emboli group, but not in the no-emboli group (P  .03).
The percentage of clear chest radiographs seen in the emboli
group was only 7%, in contrast to 43% in the no-emboli
group (Figure 1, B).
Duration of Intubation
The percentage of patients not extubated versus time after
lung transplantation was estimated by the Kaplan-Meier
method (Figure 2, A). The patients in the emboli group
remained intubated significantly longer than those in the
no-emboli group (P  .0007): the percentage of patients
who remained intubated in the emboli group was 54%,
compared with 9% in the no-emboli group, even 48 hours
after admission to the ICU.
Length of ICU Stay
The length of ICU stay in the emboli group was signifi-
cantly longer than that in the no-emboli group (Figure 2, B;
P  .0016). The percentage of patients who stayed in the
ICU longer than 7 days was 42% in the emboli group and
15% in the no-emboli group.
Acute Rejection
The percentage of patients with International Society for
Heart and Lung Transplantation grade A0 diagnosed by the
first transbronchial lung biopsy performed 2 weeks after
transplantation was 50% in the emboli group and 39% in the
Figure 2. A, Percentage of patients not extubated ve
staying in the intensive care unit versus time after trans
no-emboli groups.no-emboli group (P  .11). There was no significant dif-
The Journal of Thoracic anference in time to first acute rejection (International Society
for Heart and Lung Transplantation grade A2) between
groups (P  .34).
Lung Function 3 Months After Transplantation
The predicted forced expiratory volume in 1 second 3
months after transplantation was similar between the emboli
and no-emboli groups (74%  4% and 78%  5%, respec-
tively; P  .62).
One-Year Survival
Thirty-day, 90-day, and 1-year survival in the emboli and
no-emboli groups were 93% and 100%, 89% and 100%, and
85% and 97%, respectively (Figure E2). An early drop of
the survival curve in emboli group was seen (P  .03).
Univariate and Multivariate Analysis
Cox proportional hazard regression was constructed for the
duration of intubation, length of ICU stay, and 1-year sur-
vival. In the multivariate analysis, PE was an independent
and significant risk factor for prolonged intubation after
transplantation (hazard ratio, 2.42; 95% confidence interval,
1.25-4.70; P  .01; Table 1); however, no factors reached
statistical significance for length of ICU stay or 1-year
survival.
Subgroup Analysis of PE
In univariate analysis, both clot and fat embolism were
significant risk factors for prolonged intubation (hazard
ratio, 0.44 and 0.16; 95% confidence interval, 0.22-0.80 and
0.04-0.67; P  .02 and .01, respectively) and ICU stay
(hazard ratio, 0.52 and 0.37; 95% confidence interval, 0.29-
time after transplantation. B, Percentage of patients
tation. Comparison was made between the emboli andrsus
plan0.93 and 0.15-0.89; P  .03 and .03, respectively). There-
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to represent a higher risk factor than did clot embolism.
Risk Factors for PE
Logistic regression analysis of risk factors for PE is shown
in Table 2. Donor death due to trauma with fracture and a
smoking history of more than 20 pack-years were signifi-
cant risk factors for PE (adjusted odds ratio, 8.77 and 5.64;
95% confidence interval, 1.37-51.21 and 1.06-30.00; P 
.02 and .04, respectively).
Effect of Exploratory Flush
There was no significant difference between the exploratory
flush and no-flush groups in donor and recipient demo-
graphics except for the type of transplantation (Table E1;
P  .01). In every posttransplantation outcome variable—
TABLE 1. Cox proportional hazard regression for duration
of intubation
Variable
Hazard
ratio 95% CI P value
Univariate analysis
Pulmonary embolism 2.89 1.51-5.56 .01
Smoking 20 pack-y 2.22 1.02-4.84 .04
CPB use 5.84 2.34-14.55 .01
Underlying disease
COPD 1.00 Reference Reference
CF 1.02 0.63-1.66 .94
ILD 0.46 0.21-0.99 .04
PH 0.14 0.03-0.57 .01
Bilateral single
transplantation 0.54 0.32-0.90 .02
Multivariate analysis
Pulmonary embolism 2.42 1.25-4.70 .01
CPB use 5.98 1.47-24.40 .02
CI, Confidence interval; COPD, chronic obstructive pulmonary disease; CF,
cystic fibrosis; ILD, interstitial lung disease; PH, pulmonary hypertension;
CPB, cardiopulmonary bypass.
TABLE 2. Logistic regression analysis of risk factors for p
Variable Unadjusted odds ratio (95
Donor cause of death
Trauma 8.25 (1.45-86.83)
With fracture
Without fracture 1.53 (0.29-7.94)
CVA (hemorrhagic) 1.96 (0.42-9.11)
CVA (thrombotic) 1.22 (0.09-16.59)
Anoxia 1.00
Others 7.33 (0.48-111.11)
Smoking 20 pack-y 3.50 (0.92-13.30)
Oral contraceptives/HRT 4.78 (0.86-26.58)CI, Confidence interval; CVA, cerebrovascular accident; HRT, hormone-replace
1446.e5 The Journal of Thoracic and Cardiovascular Surgery ● Nincluding oxygenation, PVR, chest radiograph appearance,
duration of intubation, length of ICU stay, and 1-year sur-
vival—the mean value in the no-flush group tended to be
between that in the emboli and no-emboli groups.
Discussion
We have described a detailed assessment of unexpected
donor PE in lung transplantation. A deleterious effect from
unexpected PE was shown in early posttransplantation ox-
ygenation, PVR, chest radiograph, duration of intubation,
length of ICU stay, and 1-year survival. In multivariate
analysis, unexpected PE was independently and strongly
associated with prolonged intubation after transplantation.
PGF is clinically recognized as impaired gas exchange,
opacification of the chest radiograph, and increased PVR
within 24 hours of transplantation and results in the require-
ment for prolonged mechanical ventilatory support with high
levels of inspired oxygen and a prolonged stay in the ICU.
Many factors, including donor, recipient, and operative
factors, are reported as associated with PGF.5-7,18 However,
no previous prospective study has shown a statistical asso-
ciation of unexpected PE with PGF. It is important to note
that the findings of this study might explain a significant
proportion of previously unexplained PGF in lung
transplantation.
The deleterious effect of unexpected PE on lung perfor-
mance is, in part, due to mechanical obstruction. Pulmonary
arterial obstruction augments alveolar dead space and ven-
tilation/perfusion mismatch, thus resulting in impaired gas
exchange.19 At the time of procurement, ventilation/perfu-
sion mismatch might be autogenously corrected by reducing
alveolar dead space with reflex bronchoconstriction and
vasoconstriction and maintaining oxygenation and, thus, the
PaO2/FIO2 ratio. However, after transplantation, denervated
lungs might not be able to correct a ventilation/perfusion
mismatch; this would result in impaired oxygenation in the
emboli group (Figure 1, A). Additionally, the deleterious
effect of PE on the lungs might be due to its inflammatory
nary embolism
Adjusted odds ratio (95% CI) P value
8.77 (1.37-51.21) .02
2.26 (0.39-13.11) .36
1.31 (0.23-7.49) .74
0.44 (0.02-11.39) .62
1.00 Reference
6.44 (0.34-120.90) .21
5.64 (1.06-30.00) .04
9.08 (0.80-103.54) .08ulmo
% CI)ment therapy.
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activate local inflammatory mediators: this would exagger-
ate ischemia/reperfusion injury and increase endothelial
permeability. In turn, this would lead to increased interstitial
infiltration, with resultant opacity on chest radiograph (seen
in 40% of patients before and in 93% after transplantation in
the emboli group; Figure E1), and also to impaired oxygen-
ation and increased PVR (Figure 1). This inflammatory
response seems to be a nonalloimmune response, because no
effect was found in this study on acute rejection in the first lung
biopsy, time to acute rejection, and lung function 3 months
after transplantation. Further study is appropriate as local
endothelial dysfunction, exaggerated by unexpected PE,
may be important in the pathogenesis of PGF.
It is important to consider whether the presence of PE
in the donor, with its related poor early outcome, can be
predicted prospectively. In this study, donor death due to
trauma with fracture and a donor smoking history of
more than 20 pack-years were substantial risk factors for
unexpected PE (Table 2). Fracture is a common risk factor
for fat embolism, and heavy smoking, trauma, drug use,
cancer, chemotherapy, oral contraceptives, and hormone-
replacement therapy are well-recognized risk factors for
deep venous thrombosis and PE.19,20 In this study, which
primarily consisted of trauma and hemorrhagic cerebral
vascular accident donors, very few received anticoagulant
therapy because of concerns of further hemorrhage. Conse-
quently, compared with other potential organ donors,
trauma patients with fractures have a greater risk of throm-
boemboli and fat emboli.
The PaO2/FIO2 ratio before procurement in this study was
similar between the emboli and no-emboli groups. Previous
literature regarding suspected PE in the nontransplantation
population suggested that arterial blood gas analysis was not
specific and did not rule out the diagnosis of PE; also,
approximately 20% of patients with angiographically
proven PE had a normal alveolar/arterial oxygen gradient.21
Furthermore, previous transplantation literature also indi-
cates that even organ donors who died as a result of acute
PE could have an excellent PaO2/FIO2 ratio at the time of
procurement.22 Arterial blood gas analysis was not predic-
tive for unexpected PE in donor lungs.
In this study, the chest radiograph before procurement
seemed unhelpful in discriminating donors with PE from
other potential donors. Previous articles regarding imaging
studies for PE in the nontransplantation population sug-
gested that chest radiographs could not be used to diagnose
or exclude PE.19
Regarding abnormal macroscopic lung findings at the
time of procurement, Smith and colleagues23 reported a
maldistribution of preservation solution on lungs with PE
during flushing of the pulmonary arteries. In contrast,
Nguyen and colleagues24 reported that there was no evi-
The Journal of Thoracic andence of maldistribution of the preservation solution in a
donor with PE. Unfortunately, these case reports included
only 1 donor in each case. A maldistribution of preservation
solution throughout the lungs is not rare regardless of the
presence of PE and might be associated with other circum-
stances, including poorly ventilated areas, lung contusions,
or local vasoconstriction.25 The authors of these 2 case
reports also described successful thromboembolectomy for
unexpected PE at the time of donor lung preparation before
implantation. However, in this study, unexpected PE could
be detected only by direct vision through the pulmonary
arterial cuff in 2 of 28 donors in the emboli group; other-
wise, PE was isolated to the subsegmental pulmonary ar-
teries or more distal branches. Isolated PE of the subseg-
mental pulmonary arteries is not unusual and occurred in
30% of patients with PE in a previous nontransplantation
pulmonary angiographic study.26 We believe that an explor-
atory flush may be the only diagnostic method of detecting
unexpected PE isolated in subsegmental pulmonary arteries.
In comparison between the exploratory flush and no-
flush groups, no direct effect of the exploratory flush itself
on lungs was seen. In other words, the exploratory flush
seemed not to either improve or exacerbate lung function.
Therefore, the exploratory flush seems to function as a diag-
nostic method and not as a treatment. Further therapeutic
strategies might be warranted for patients in emboli group.
To remove the residual emboli, a retrograde full-dose
flush with mechanical ventilation might be beneficial.14,15,27
Venuta and associates15 observed blood, clot, and fat in the
retrograde perfusate in all 7 patients described in the liter-
ature of their clinical experience of preimplantation retro-
grade preservation flush (30-40 mL/kg). de Perrot and
Keshavjee14 mentioned the potential of retrograde preser-
vation flush to remove residual blood, clot, and PE. The
endothelium of the pulmonary artery with PE already dam-
aged at the time of procurement is aggravated by maldistri-
bution of preservation solution, and this has implications for
ischemia/reperfusion injury. Retrograde flush at the time of
procurement might have a more protective effect on dam-
aged endothelium (by uniform distribution of flush solution)
than that at the time of implantation. However, the routine
application of a large-volume retrograde flush might not be
necessary, because patients without PE in this study had sat-
isfactory outcomes without a large-volume retrograde flush.
Previously, 2 case reports described successful use of
lungs from fatal acute PE donors treated by thrombolysis
several days before organ procurement.22,28 Dissolving and
removing PEs is effective; however, careful consideration is
necessary when thrombolysis is applied to lungs with un-
expected PE because of the risk of postoperative bleeding.
Other therapeutic strategies to prevent ischemia/reperfu-
sion injury, such as using complement inhibitor29 and an-
tagonist of platelet-activating factor,30 have been investi-
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exploratory flush could distinguish specific donor lungs at
high risk of early graft dysfunction that would require
further therapeutic approaches. This may contribute to bet-
ter patient outcomes with cost-effectiveness.
A possible limitation to this study should be considered.
Data regarding the result of exploratory flush were collected
prospectively; however, this study had prospective and ret-
rospective components, and, therefore, there might be a
potential bias in selecting patients into the flush or no-flush
groups. The incidence of PE between February 2004 and
April 2005, when exploratory flush was routinely per-
formed, was 38% (18/47)—equal to the overall incidence of
PE (38%; 28/74). Although the incidence of PE in the
no-flush group was unknown, in every posttransplantation
outcome variable the mean value in the no-flush group
tended to be between that in the emboli and no-emboli
groups. This result supports the notion that there was likely
to be a similar distribution of patients with emboli between
the flush and no-flush groups.
In conclusion, this is the first study that has described a
detailed analysis of donor-related unexpected PE in lung
transplantation. The incidence of unexpected PE is high.
Unexpected PE is potentially predicted by a donor history of
trauma with fracture and smoking more than 20 pack-
years—not by donor arterial blood gas analysis or chest
radiograph. Unexpected PE is associated with PGF. There-
fore, donors with risk factors for unexpected PE should be
considered as marginal donors for lung transplantation. All
the lung grafts of donors with risk factors of unexpected PE
should undergo an exploratory flush. When PE is diagnosed,
further therapeutic strategies must be considered.
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Oto et al Cardiothoracic TransplantationTABLE E1. Demographics of donor and recipient
Variable
Exploratory flush (n  74)
No flush
(n  48) P value
Emboli
(n  28)
No emboli
(n  46) P value
Donor
Age, y (mean  SE) 33 3 38  2 .2 36  2 .2
Sex .2 .2
Male 20 31 31
Female 8 15 17
Oral contraceptives/HRT 4 2 .2
Smoking 20 pack-y 6 4 .2 6 .2
Cause of death .2 .2
Trauma
With fracture 9 4 8
Without fracture 5 12 11
CVA
Hemorrhagic 8 15 15
Thrombotic 1 3 5
Anoxia 3 11 7
Others 2 1 2
Anticoagulant therapy 1 5 .2 2 .2
Preprocurement intubation time, h (mean  SE) 53 6 61  9 .2 61  5 .2
Preprocurement PaO2/FIO2 455 21 474  12 .2 474  12 .2
Recipient
Age, y (mean  SE) 45 3 47  2 .2 48  2 .2
Sex .2 .2
Male 17 33 30
Female 11 13 18
Underlying disease .2
COPD 11 21 19
CF 8 18 16
ILD 4 5 11
PH 5 2 2
Type of transplantation .2 .01
Bilateral 24 35 27
Single 4 11 21
CPB use 9 6 .05 6 .2
Ischemic time, min (mean  SE) 368 26 370  20 .2 379  19 .2
HRT, Hormone-replacement therapy; CVA, cerebrovascular accident; PaO2/FIO2, ratio of arterial oxygen tension and inspired oxygen fraction; COPD, chronic
obstructive pulmonary disease; CF, cystic fibrosis; ILD, interstitial lung disease; PH, pulmonary hypertension; CPB, cardiopulmonary bypass.The Journal of Thoracic and Cardiovascular Surgery ● Volume 130, Number 5 1446.e8
Cardiothoracic Transplantation Oto et alFigure E1. A, Percentage of donor chest radiographs showing infiltrate before procurement. B, Percentage of
recipient chest radiographs showing infiltrate 24 hours after transplantation.Figure E2. One-year survival. Comparison was made between the
emboli and no-emboli groups.
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